• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

TIMs make impact on infants

Article

Winston-Salem, N.C. - Separate studies involving atopic dermatitis drugs tacrolimus (Protopic) and pimecrolimus (Elidel) show the topical immunomodulators (TIMs) are safe and effective for off-label use on children under age 2.

Recent Videos
Related Content
Research Observe, Classify Adverse Event Profiles for Pediatric Patients Treated With JAK Inhibitors

Research Observe, Classify Adverse Event Profiles for Pediatric Patients Treated With JAK Inhibitors

Article
The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis

The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis

Podcast
Case of Juvenile Bullous Pemphigoid with Negative Serum BP180 ELISA Test Reveals Need for Additional Testing

Case of Juvenile Bullous Pemphigoid with Negative Serum BP180 ELISA Test Reveals Need for Additional Testing

Article
The Cutaneous Connection

The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma

Podcast
“My Skin My Story” Provides Creative Outlet for Young Patients With Eczema

“My Skin My Story” Provides Creative Outlet for Young Patients With Eczema

Article
Q&A: Biologic Therapies in Pediatric Dermatology - Vaccines, Adverse Effects, and Personalized Care

Q&A: Biologic Therapies in Pediatric Dermatology - Vaccines, Adverse Effects, and Personalized Care

Article
© 2024 MJH Life Sciences

All rights reserved.